538372-37-1

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 3,4-diamino-2-methoxy-, methyl ester (9CI) is used as a reactant in the synthesis of DNA-binding oligomers for various pharmaceutical applications. These oligomers have the potential to interact with DNA and modulate gene expression, making them valuable tools in the development of new drugs and therapies.
Used in Research and Development:
In addition to its pharmaceutical applications, Benzoic acid, 3,4-diamino-2-methoxy-, methyl ester (9CI) is also used in research and development settings. Scientists and researchers utilize Benzoic acid, 3,4-diamino-2-methoxy-, methyl ester (9CI) to study the interactions between DNA and various chemical agents, as well as to develop new methods for synthesizing DNA-binding oligomers.
Used in Chemical Synthesis:
Benzoic acid, 3,4-diamino-2-methoxy-, methyl ester (9CI) is a versatile building block in chemical synthesis, allowing for the creation of a wide range of compounds with diverse applications. Its unique structure and reactivity make it a valuable component in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.

Upstream product

• 20896-27-9 methyl 4-amino-5-chloro-2-methoxybenzoate 
• 126463-85-2 4-acetylamino-5-chloro-2-methoxy-3-nitro-benzoic acid methyl ester 
• 4093-31-6 methyl 2-methoxy 4-acetamido 5-chloro benzoate 
• 457947-61-4 4-amino-5-chloro-2-methoxy-3-nitro-benzoic acid methyl ester 

Downstream Products

• 861259-01-0 2-(2,3-dichloro-phenylamino)-4-methoxy-3H-benzoimidazole-5-carboxylic acid methyl ester 
• 251107-34-3 3,4-diamino-2-methoxybenzoic acid 

Relevant academic research and scientific papers

ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS

Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

ORGANIC COMPOUNDS

Compounds of formula (I) in free or salt form, where Y, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the CXCR2 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Alternative heterocycles for DNA recognition

Methods and compositions are provided for forming complexes between dsDNA and novel oligomers comprising fused six-membered rings. By appropriate choice of target sequences and oligomers, complexes comprising oligomer-DNA are obtained with high association constants. The formation of complexes can be used for identification of specific dsDNA sequences, for inhibiting gene transcription, and as a therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific genes.

Imidazopyridine/pyrrole and hydroxybenzimidazole/pyrrole pairs for DNA minor groove recognition

The DNA binding properties of fused heterocycles imidazo[4,5-b]pyridine (Ip) and hydroxybenzimidazole (Hz) paired with pyrrole (Py) in eight-ring hairpin polyamides are reported. The recognition profile of Ip/Py and Hz/Py pairs were compared to the five-m